This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Judith E. Fradkin, MD; Phillip Gorden, MD
National Institute of Diabetes and Digestive and Kidney Disease National Institutes of Health Bethesda, Md

JAMA. 1994;271(16):1240.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The article by Drs Wilfond and Nolan¹ is inaccurate with respect to the role of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in cystic fibrosis (CF) carrier screening. Having supported CF gene identification, the NIDDK felt an obligation to ensure responsible use of the information. In response to concerns about screening the population prematurely, the NIDDK convened a distinguished panel 6 months after the gene identification to discuss the principles and preconditions for carrier screening. The recommendations of this group are widely accepted and have been reiterated in subsequent position papers by the American Society of Human Genetics (ASHG). The NIDDK response was timely and appropriate. The statement by Wilfond and Nolan, "Thus, almost by default, ASHG was placed in the position of responding to... and organizing an NIH [National Institutes of Health] workshop to develop policy guidelines," is incorrect. The NIH . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?